NEW YORK (GenomeWeb News) – Pharmaceutical company Amgen has signed a multi-year license agreement to use BioWisdom’s knowledge network software, BioWisdom said today.
 
BioWisdom’s Sofia software is used to format large amounts of complex data that drug developers generate in their research. The Cambridge, UK-based firm said the software creates “Intelligence Networks, a unique format of assertional metadata that liberates knowledge from structured and unstructured data, regardless of its original format.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.